Lipid nanoparticles – Metvan: revealing a novel way to deliver a vanadium compound to bone cancer cells

CACICEDO, MAXIMILIANO; RUIZ, MARIA ESPERANZA; BARAN, ENRIQUE J; RUIZ, MARIA CAROLINA; FERNANDEZ, MARIELA; CASTRO, GUILLERMO R.; SCIOLI MONTOTO, SEBASTIAN; TORRES SANCHEZ, ROSA M; LEON, IGNACIO

NEW JOURNAL OF CHEMISTRY

ROYAL SOC CHEMISTRY

Lugar: CAMBRIDGE; Año: 2019 vol. 43 p. 17726 - 17734

1144-0546

Cancer is one of the main causes of mortality worldwide. Common therapy schemes are always based on chemotherapy, radiotherapy and/or surgery. Among chemotherapeutics, vanadium compounds have recently emerged as non-platinum antitumor agents.In this sense, Metvan ([VIVO(Me2phen)2(SO4)]) was identified as one of the most promising vanadium anticancer complexes. In this work, Metvan compound was encapsulated into well designed and developed nanostructured lipid carriers (NLCs) with the aim of improving its biopharmaceutical profile by means of bioavailability, degradation, solubility and cell up-take. A quality by design approach was performed to find the optimal nanoparticle formulation for Metvan delivery. Results exhibited that the ideal formulation was obtained by using myristyl myristate as the lipid matrix and Pluronic F128 as the stabilizing agent with a mean nanoparticle size of 230.8 ± 3.1 nm and a mean surface charge of -7.9 ± 0.8 mV. The formulation showed an encapsulation efficiency of approximately 80% with a drug sustained release for more than 60 h. The kinetic release mechanism of Metvan from nanoparticles fitted Korsmeyer?Peppas model, indicating the Fickian diffusion of Metvan from the nanoparticles. On the other hand, the results showed that the nanoparticles-Metvan system is more effective to decrease cell viability on human osteosarcoma cells (MG-63) than free drug, suggesting a possible different cell internalization mechanism and intracellular effect.